Achievable complete remission of advanced non-small-cell lung cancer: Case report and review of the literature

作者：Yang Ning Ning; Xiong Fei; He Qing; Guan Yong Song^*

来源：World Journal of Clinical Cases, 2018, 6(7): 150-155.

DOI：10.12998/wjcc.v6.i7.150

• Tyrosine kinase inhibitor
• Bronchial artery infusion
• Icotinib hydrochloride
• Epidermal growth factor receptor
• Advanced non-small-cell lung cancer

Surgery is the first choice of treatment for patients with non-small-cell lung cancer (NSCLC), but few patients can be treated surgically because of either advanced disease or poor pulmonary function. Other therapies include radiotherapy and chemotherapy, as well as complementary and alternative therapies, usually with disappointing results. Bronchial artery infusion (BAI) is a manageable and effective method for treating advanced NSCLC. Outcome is good by BAI due to its repeatability and low toxicity. Icotinib hydrochloride is a newly developed and highly specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and has been safely and efficiently used to treat advanced NSCLC. We herein report a 73-year-old patient with chronic cough, who was diagnosed with advanced NSCLC with the EGFR mutation of L858R substitution in exon 21, and treated with the combination of oral icotinib and BAI chemotherapy as the first-line therapy, which resulted in a satisfactory clinical outcome. Complete remission of advanced NSCLC can be achieved using the combination of oral icotinib and BAI chemotherapy.

• 出版日期2018-7-16
• 单位四川大学